ClinicalTrials.Veeva

Menu

An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Stage V Chronic Kidney Disease Participants on Hemodialysis

Roche logo

Roche

Status

Completed

Conditions

Anemia

Treatments

Drug: Methoxy polyethylene glycol epoetin beta

Study type

Observational

Funder types

Industry

Identifiers

NCT01940484
ML22344

Details and patient eligibility

About

This observational study will evaluate the efficacy and use of Methoxy polyethylene glycol-epoetin beta (Mircera) in participants with Stage V chronic kidney disease on hemodialysis receiving an erythropoietin prior to study entry. Attending physicians should have made the decision of placing the participant on methoxy polyethylene glycol epoetin beta in advance and not related to the study. The therapy will be administered by the attendant treating physician according to specifications in the package insert guidelines and to the routine of the site.

Enrollment

98 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Participants with chronic renal anemia with Stage V chronic kidney disease on hemodialysis and with a hemoglobin level of 10.0 - 13.0 grams per deciliter (g/dL)
  • Participants had to be receiving an ESA prior to entering the study
  • Female participants of childbearing age had to be using effective contraceptive methods

Exclusion criteria

  • As per approved package insert
  • Any contraindication to ESA treatment

Trial design

98 participants in 1 patient group

Chronic Renal Anemia Participants
Description:
Participants with chronic kidney disease and who are on hemodialysis and on methoxy polyethylene glycol epoetin beta as per physician's discretion for treatment of chronic renal anemia will be observed for a period of 6-12 months.
Treatment:
Drug: Methoxy polyethylene glycol epoetin beta

Trial contacts and locations

10

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems